Medicare Part B Drug Reimbursement Program Distresses Pharmacy Players: Program Seeks to Reduce Use of Expensive Biologics.

346 P&T® • June 2016 • Vol. 41 No. 6 The new Medicare drug-pricing program1 aimed at cutting reimbursement for Part B drugs will hit hospitals hardest, according to the Centers for Medicare and Medicaid Services (CMS). The drugs at issue are typically chemotherapy, ophthalmic, or rheumatoid arthritis drugs infused in a physician’s offi ce or a hospital outpatient clinic. Medicare reimburses either the physician or the hospital—and sometimes a specialty pharmacy—under Medicare Part B. Very occasionally those drugs are paid for under the Part D outpatient drug program. The plan has proven controversial. Oncologists have led the charge to force the CMS to backtrack, and allies, both Republican and Democrat, in Congress have sent the CMS letters of opposition and, in at least one case, introduced Republican-sponsored legislation to thwart the plan. The AARP and parts of the insurance industry are trying to stiffen the CMS’s spine. Medicare spent $22 billion on Part B drugs in 2015. In 2007, the total payments were $11 billion; the average annual increase since 2007 has been 8.6%. This growth has been driven largely by spending on separately paid drugs in the hospital outpatient setting, which more than doubled between 2007 and 2015, from $3 billion to $8 billion, respectively. Currently, physicians and clinics receive 6% of the average sales price (ASP) of the drug as their “profi t” on infusion. But in reality, that 6% margin was reduced to 4.3% because of language in the 2012 Congressional budget sequester legislation that cut federal spending in most programs. The CMS announced a fi ve-year test program in which the fi rst phase will see Mr. Barlas is a freelance writer in Washington, D.C., who covers issues inside the Beltway. Send ideas for topics and your comments to sbarlas@ verizon.net. Medicare Part B Drug Reimbursement Program Distresses Pharmacy Players